NCT05860010

Brief Summary

Electrical cardiometry (EC) is a non-invasive method of estimating cardiac parameters by measuring changes in thoracic bioimpedance during the cardiac cycle. The ICON (Cardiotronic Osypka Medical, San Diego, California) monitor uses four electrocardiogram electrodes and estimates the maximum rate of impedance change to peak aortic blood acceleration. An impedance change occurs between diastole and systole as red blood cell orientation is altered from random during diastole to align during systole. This device is validated against Fick cardiac output and transthoracic echocardiography in infants and children, as well as thermodilution in adults with R values of 0.9. This device is approved by the Food and Drug Administration (FDA) for use in pediatrics. Hypotension is expected to occur after epidural anesthesia (EA) due to the dilatation of venous vessels by sympathetic blockade with a subsequent decrease in venous return and cardiac output (CO). Also, the association of general anesthesia (GA) to EA can lead to more decrease in CO. The addition of epinephrine to local anesthetics (LA) could worsen hypotension through the systemic absorption of epinephrine that leads to a vasodilator β effect. Yet, CO may be enhanced by this β-adrenergic stimulation. However, it is well known that caudal epidural anesthesia has few or no hemodynamic changes in children less than 8 yr old. This could be attributed to the immaturity of their sympathetic system and smaller lower-limbs blood volume compared to adults. Caudal anesthesia is highly effective in abdominal, urinary tract, and lower extremity surgeries in children for intra- and postoperative analgesia. The addition of dexmedetomidine to local anesthetics in caudal anesthesia is a frequent practice. Dexmedetomidine, a highly selective alpha-2 adrenoreceptor agonist, is used as an intravenous sedative and analgesic drug. It has an a2/a1 selectivity ratio of 1600: 1 and is eight times more potent than clonidine. Intrathecal and epidural dexmedetomidine have been reported to produce analgesic properties, prolonging the duration of local anesthetics without causing nerve damage in pediatric patients. Although basal heart rate is greater than in adults, activation of the parasympathetic nervous system, anesthetic overdose, or hypoxia can quickly trigger bradycardia and profound reductions in cardiac output. The sympathetic nervous system and baroreceptor reflexes are not fully mature and the infant cardiovascular system displays a blunted response to exogenous catecholamines. That's why it is very essential to determine the hemodynamic effects of any drug used as an adjuvant to local anesthetics for caudal block and to explore whether it reduces the child cardiac output or not. As invasive cardiac monitors are rarely indicated in pediatric patients, and little is known about the impact of caudally administered dexmedetomidine on cardiac function, so we aimed to investigate its effect on hemodynamic functions measured by EC.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
39

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 4, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

May 16, 2023

Completed
20 days until next milestone

Study Start

First participant enrolled

June 5, 2023

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 5, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 5, 2023

Completed
Last Updated

May 16, 2023

Status Verified

May 1, 2023

Enrollment Period

5 months

First QC Date

March 4, 2023

Last Update Submit

May 7, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • The percentage change in cardiac output after caudal injection

    the change of cardiac output before and after caudal injection in percent

    15 minutes after caudal injection

Study Arms (3)

control

PLACEBO COMPARATOR

Bupivacaine will be administered in the caudal space

Drug: Bupivacaine

dexmedetomidine

ACTIVE COMPARATOR

caudal with dexmedetomidine

Drug: DexmedetomidineDrug: Bupivacaine

epinephrine

ACTIVE COMPARATOR

caudal with epinephrine

Drug: Epinephrine injectionDrug: Bupivacaine

Interventions

patients will be placed on left lateral position and drug will be given the caudal space

epinephrine

patients will be placed on left lateral position and drug will be given the caudal space

dexmedetomidine

patients will be placed on left lateral position and drug will be given the caudal space

controldexmedetomidineepinephrine

Eligibility Criteria

Age2 Months - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • ASA physical status I and II, pediatric patients aged between 6 months and 8 years, of male or female gender, and undergoing elective infraumbilical (i.e. lower abdominal or genitourinary surgeries) will be included.

You may not qualify if:

  • Parent or guardian refusal
  • Patients \< 6 months and \> 8 years old
  • Emergency cases
  • Surgery lasting \> 60 min
  • Patients with known congenital heart disease.
  • Patients with history or evidence of infection at the back.
  • Congenital abnormalities of lower spine or meninges e.g. spina bifida
  • Patients with blood clotting disorders or on anticoagulation therapy.
  • Patients with known allergy to systemic or local anesthetics

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Ayman Abougabal [aabougabal]

Cairo, 12566, Egypt

Location

Kasr Al Ainy

Cairo, 12566, Egypt

Location

MeSH Terms

Interventions

EpinephrineDexmedetomidineBupivacaine

Intervention Hierarchy (Ancestors)

EthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesBiogenic MonoaminesBiogenic AminesCatecholaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsAnilidesAmidesAniline Compounds

Central Study Contacts

Ayman amin A Abougabal

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
consultant of anesthesia

Study Record Dates

First Submitted

March 4, 2023

First Posted

May 16, 2023

Study Start

June 5, 2023

Primary Completion

November 5, 2023

Study Completion

December 5, 2023

Last Updated

May 16, 2023

Record last verified: 2023-05

Data Sharing

IPD Sharing
Will share

Locations